AR042572A1 - Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos - Google Patents

Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos

Info

Publication number
AR042572A1
AR042572A1 ARP000101441A ARP000101441A AR042572A1 AR 042572 A1 AR042572 A1 AR 042572A1 AR P000101441 A ARP000101441 A AR P000101441A AR P000101441 A ARP000101441 A AR P000101441A AR 042572 A1 AR042572 A1 AR 042572A1
Authority
AR
Argentina
Prior art keywords
radical
linear
branched
hydrogen atom
group
Prior art date
Application number
ARP000101441A
Other languages
English (en)
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9904132A external-priority patent/FR2791677B1/fr
Priority claimed from FR0002315A external-priority patent/FR2805537A1/fr
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of AR042572A1 publication Critical patent/AR042572A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid

Abstract

Derivados de ácido lipoico que responden al grupo de sub-fórmula (1), en donde los sustituyentes tienen los significados dados en la reivindicación 1. Dichos derivados tienen una actividad inhibidora sobre las enzimas NO-sintasa que producen monóxido de nitrógeno NO y/o que son agentes que permiten la regeneración de antioxidantes o de entidades que entrampan las especies de oxígeno reactivo (ROS, reactive oxygen species) y que intervienen de una manera más general en el status de redox de los grupos tiol. También se describen procedimiento para su preparación, los medicamentos y las composiciones farmacéuticas que los contienen, y su utilización para preparar medicamentos que tienen fines terapéuticos, en particular su utilización como inhibidores de la NO-sintasa y/o como agentes que intervienen de una manera más general en el status de redox de los grupos tiol. Reivindicación 1: Un producto de la fórmula general (1),caracterizado porque comprende los productos del grupo sub-fórmula (1), en las cuales: R1 y R2 representan independientemente entre sí un átomo de hidrógeno o un radical alquilo lineal o ramificado C1-6; A representa uno de los siguientes radicales: -(CH2)m-NR3-CO(CH2)n-, -(CH2)m-CO-NR3-(CH2)n-, -(CH2)m-NR3-(CH2)n-, -(CH2)m-CONR3-(CH2)p-NR4-(CH2)n-, -(CH2)m-NR3-CO-NR4-(CH2)n-, ó -(CH2)m-, siendo m y n, números enteros de 0 a 6, siendo p un número entero de 2 a 6, y representando R3 y R4, independientemente entre sí, un átomo de hidrógeno o un radical alquilo C1-4 lineal o ramificado; X representa el radical de fórmula (2), en el cual el grupo T, que está fijado al grupo Y, representa un radical -(CH2)i-, en el cual i representa un número entero entre 0 y 6, y R5 representa un átomo de hidrógeno, un radical alquilo lineal o ramificado C1-6 o un radical (CH2)m-Q en el cual Q representa un átomo de halógeno o un radical hidroxi, ciano, amino, alcoxi, alquiltio, alquilamino o dialquil amino, o también R5 representa un heterociclo con 5 ó 6 miembros cuyos miembros heterocíclicos son seleccionados entre los siguientes radicales: -O-, -N(R6)- y -S-, representando R6 un átomo de hidrógeno, un alquilo lineal o ramificado de 1 a 6 átomos, o el enlace hacia el ciclo fenilo del radical X; o, X representa un radical -(CH2)q- en el cual q representa un número entero de 0 a 6; y finalmente Y representa un de los siguientes radicales de grupo de fórmula (3), en los cuales: B representa un radical alquilo C1-6 lineal o ramificado, arilo carbocíclico o heterocíclico con 5 ó 6 miembros que contienen de 1 a 4 heteroátomos seleccionados de entre el grupo consistente en O, S, N, y en particular los radicales tiofeno, furano, pirrol o tiazol, estando el radical arilo opcionalmente sustituido por uno o más grupos seleccionados de entre el grupo consistente en los radicales alquilo, alquenilo o alcoxi, lineales o ramificados C1-6, o B representa NR8R9, representando R8 y R9, independientemente entre si, un átomo de hidrógeno o un radical alquilo lineal o ramificado C1-6, o uno de los mismos, R8 ó R9, representa un radical nitro mientras que el otro representa un átomo de hidrógeno o un radical alquilo lineal o ramificado C1-6, o R8 y R9 forman conjuntamente con el átomo de nitrógeno un heterociclo no aromático con cinco o seis miembros, siendo los elementos de la cadena, seleccionada de entre el grupo consistente en: -CH2-, -O- ó -S-; o también, B representa un radical SR10 en el cual R10 representa un átomo de hidrógeno o un radical alquilo C1-6, lineal o ramificado; y R7 representa un átomo de hidrógeno o un radical alquilo C1-6, lineal o ramificado; o una sal de un producto de la fórmula general (1).
ARP000101441A 1999-04-02 2000-03-30 Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos AR042572A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9904132A FR2791677B1 (fr) 1999-04-02 1999-04-02 Nouveaux derives de l'acide lipoique, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
FR0002315A FR2805537A1 (fr) 2000-02-24 2000-02-24 Nouveaux derives de l'acide lipoique, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant

Publications (1)

Publication Number Publication Date
AR042572A1 true AR042572A1 (es) 2005-06-29

Family

ID=26212205

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000101441A AR042572A1 (es) 1999-04-02 2000-03-30 Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos

Country Status (20)

Country Link
US (2) US6605637B1 (es)
EP (1) EP1169316B9 (es)
JP (1) JP2003505341A (es)
KR (1) KR100758763B1 (es)
CN (1) CN1173969C (es)
AR (1) AR042572A1 (es)
AT (1) ATE233752T1 (es)
AU (1) AU763572B2 (es)
CA (1) CA2369071A1 (es)
DE (1) DE60001546T9 (es)
DK (1) DK1169316T3 (es)
ES (1) ES2193949T3 (es)
HK (1) HK1046134B (es)
HU (1) HUP0200863A3 (es)
MY (1) MY119231A (es)
NZ (1) NZ514888A (es)
PL (1) PL350994A1 (es)
PT (1) PT1169316E (es)
TW (1) TWI269794B (es)
WO (1) WO2000059899A1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19941217A1 (de) * 1999-08-30 2001-03-15 Asta Medica Ag Behandlung der Migräne durch Verabreichung von alpha-Liponsäure oder Derivaten derselben
PT1265891E (pt) 2000-03-16 2005-04-29 Conseils Rech S Et D Applic Sc Novos derivados heterociclicos ou benzenicos do acido lipoico sua preparacao e sua aplicacao a titulo de medicamentos
IT1319196B1 (it) * 2000-10-10 2003-09-26 Laboratorio Chimico Int Spa Sintesi dell'acido r(+)alfa-lipoico.
DK1339705T3 (da) 2000-11-30 2006-10-09 Basf Ag Fremgangsmåde til fremstilling af liponsyre og dihydroliponsyre
DE10137381A1 (de) * 2001-07-31 2003-02-13 Viatris Gmbh Neue Modifikationen des Trometamolsalzes der R-Thioctsäure sowie Verfahren zu ihrer Herstellung
JP2005503872A (ja) * 2001-09-28 2005-02-10 メーガン メディカル、インク． 経皮鍼電気信号を制御するための方法と装置
WO2004043485A1 (fr) * 2002-11-10 2004-05-27 Institute Of Cell Biophysics Russian Academy Of Sciences Composition presentant des proprietes antioxydantes, procede de production d'un polypeptide et methode de traitement
US7202270B2 (en) * 2003-06-20 2007-04-10 Sami Labs Limited Convenient stable non-hygroscopic crystalline solid forms of racemic and chiral LA-plus salts: process for their manufacture and uses
US8916546B2 (en) 2003-08-29 2014-12-23 Therapeutic Research Llc Materials and methods for treatment and diagnosis of disorders associated with oxidative stress
US20070299093A1 (en) * 2005-01-27 2007-12-27 Alma Mater Studiorum-Universitá Di Bologna Organic Compounds Useful for the Treatment of Alzheimer's Disease, Their Use and Method of Preparation
WO2006080043A2 (en) * 2005-01-27 2006-08-03 Alma Mater Studiorum- Universita' Di Bologna Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation
PT1754478E (pt) * 2005-08-04 2009-03-31 Encrypta Gmbh Composição líquida compreendendo arginina e ácido alfalipóico e sua utilização para melhorar a função sexual
FR2908769B1 (fr) * 2006-11-17 2008-12-26 Oreal Nouveaux composes derives dithiolanes silicies et leur utilisation
WO2008106640A1 (en) * 2007-03-01 2008-09-04 Cedars-Sinai Medical Center Antioxidant polymers containing [1,2]-dithiolane moieties and uses thereof
EP2139321B1 (en) * 2007-04-18 2013-11-06 Cornerstone Pharmaceuticals, Inc. Lipoic acid derivatives
MX2009013683A (es) 2007-06-13 2010-04-07 Jay Pravda Materiales y metodos para el tratamiento y diagnostico de trastornos asociados con estres oxidativo.
DE102007038849A1 (de) 2007-08-16 2009-02-19 Adscil Gmbh Verwendung von R(+)-alpha-Liponsäure zur Behandlung der kryptogenen Neuropathie
US9028874B2 (en) * 2008-01-03 2015-05-12 Cedars-Sinai Medical Center Antioxidant nanosphere comprising [1,2]-dithiolane moieties
CA2720396A1 (en) * 2008-04-04 2009-10-08 Robert Shorr Pharmaceutical composition
EP2300451A1 (en) 2008-06-02 2011-03-30 Cedars-Sinai Medical Center Nanometer-sized prodrugs of nsaids
FR2937035B1 (fr) * 2008-10-10 2010-12-31 Oreal Composes dithiolanes ; compositions les contenant ; utilisations pour la photoprotection de la peau
WO2010047793A2 (en) 2008-10-21 2010-04-29 The General Hospital Corporation Cell transplantation
KR101493125B1 (ko) 2008-11-24 2015-02-12 세다르스-신나이 메디칼 센터 항산화성 캠토테신 유도체 및 이들의 항산화성 항종양성 나노구체
CN102395560A (zh) * 2009-02-17 2012-03-28 因瓦斯科医疗有限公司 包括一氧化氮的二氢硫辛酸衍生物及其治疗应用
US8632512B2 (en) 2010-04-09 2014-01-21 Kci Licensing, Inc. Apparatuses, methods, and compositions for the treatment and prophylaxis of chronic wounds
CN103153376B (zh) 2010-08-06 2018-04-20 通用医院公司以麻省总医院名义经营 用于细胞处理相关应用的系统和设备
US8529873B2 (en) 2011-08-24 2013-09-10 Los Alamos National Security, Llc SE-72/AS-72 generator system based on Se extraction/ As reextraction
CA2891090A1 (en) 2012-11-09 2014-05-15 Scidose, Llc Enema composition for treatment of ulcerative colitis having long term stability
WO2015195070A1 (en) 2014-06-19 2015-12-23 Robert Shorr Pharmaceutical compounds
EP3188726B1 (en) 2014-06-19 2019-08-07 Rafael Pharmaceuticals, Inc. Pharmaceutical compounds
CN105949180B (zh) * 2016-05-10 2018-07-10 中山大学 治疗中枢神经系统退行性疾病的化合物及其应用
CN106279136B (zh) * 2016-08-15 2019-06-21 中山大学 治疗中枢神经系统退行性疾病或脑肿瘤的化合物及其应用
CN106957298B (zh) * 2017-04-18 2019-07-16 湖南中医药大学 一种硫辛酸苯酚酯衍生物及其制备方法和应用
CN107382987A (zh) * 2017-07-19 2017-11-24 佛山市第五人民医院 一种具有预防和治疗创伤性脑损伤活性的化合物及其制备方法和用途
CN111683976B (zh) 2018-02-05 2022-11-18 生物辐射实验室股份有限公司 具有阴离子交换-疏水混合模式配体的色谱树脂
CN112999220B (zh) * 2021-04-07 2022-12-13 中国人民解放军南部战区总医院 α-硫辛酸在作为和/或制备金属β-内酰胺酶抑制剂中的应用
CN115778930B (zh) * 2022-12-08 2024-02-27 陕西中医药大学 一种具有血管舒张活性的二硫缩醛类化合物在制备具有血管舒张活性药物方面的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1205972B (de) * 1963-08-20 1965-12-02 Merck Ag E Verfahren zur Herstellung eines Liponsaeure-derivates
US4938636A (en) 1988-11-14 1990-07-03 Aidlin Automation Corp. Method and apparatus for feeding container bodies
JPH06250330A (ja) * 1993-03-01 1994-09-09 Konica Corp 写真フィルムの加工方法
AU728488B2 (en) * 1997-04-02 2001-01-11 Sankyo Company Limited Dithiolan derivatives, their preparation and their therapeutic effect
KR20010072080A (ko) * 1998-07-31 2001-07-31 쓰끼하시 다미까따 페닐아졸 화합물, 그의 제조 방법 및 고지혈증용 약제
CA2348998C (en) * 1998-10-26 2012-03-06 The Research Foundation Of State University Of New York Lipoic acid derivatives and their use in treatment of disease
AU7995300A (en) * 1999-10-05 2001-05-10 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
US6492405B2 (en) * 1999-12-30 2002-12-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nitric oxide donors and pharmaceutical compositions containing them
US6387945B2 (en) * 2000-04-11 2002-05-14 The Regents Of The University Of California Lipoic acid analogs

Also Published As

Publication number Publication date
US20040019084A1 (en) 2004-01-29
ATE233752T1 (de) 2003-03-15
DE60001546T9 (de) 2004-11-04
JP2003505341A (ja) 2003-02-12
WO2000059899A8 (fr) 2001-03-22
KR20010108444A (ko) 2001-12-07
HK1046134A1 (en) 2002-12-27
EP1169316B9 (fr) 2003-10-29
PL350994A1 (en) 2003-02-24
CN1349523A (zh) 2002-05-15
DK1169316T3 (da) 2003-06-30
CN1173969C (zh) 2004-11-03
HUP0200863A2 (en) 2002-08-28
EP1169316B1 (fr) 2003-03-05
NZ514888A (en) 2002-12-20
WO2000059899A1 (fr) 2000-10-12
AU3970900A (en) 2000-10-23
TWI269794B (en) 2007-01-01
AU763572B2 (en) 2003-07-24
PT1169316E (pt) 2003-07-31
CA2369071A1 (fr) 2000-10-12
ES2193949T3 (es) 2003-11-16
KR100758763B1 (ko) 2007-09-14
DE60001546T2 (de) 2004-02-19
US6605637B1 (en) 2003-08-12
MY119231A (en) 2005-04-30
DE60001546D1 (de) 2003-04-10
HUP0200863A3 (en) 2005-02-28
EP1169316A1 (fr) 2002-01-09
HK1046134B (zh) 2005-04-22
US6887891B2 (en) 2005-05-03

Similar Documents

Publication Publication Date Title
AR042572A1 (es) Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos
EA200870192A1 (ru) Новые серосодержащие производные циклической мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназ
AR033989A1 (es) Un compuesto derivado de la 3-indolil-4-fenil-1h-pirrol-2,5-diona, un metodo para prepararlo, y un medicamento que lo contiene
ATE557002T1 (de) Verbindungen mit calcimimetischer wirkung
PA8580501A1 (es) Derivados de indol o derivados de bencimidazol para modular ikb quinasa
ES2190396T3 (es) Nuevos compuestos amino-triazoles, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
NO20062135L (no) Fenylderivater som PPAR-agonister
PL401636A1 (pl) Związek benzoimidazolowy, jego zastosowanie oraz zawierająca go kompozycja farmaceutyczna
ES2181803T3 (es) Acidos 4-biarilbutiricos o 5-biarilpentanoicos sustituidos y sus derivados como inhibidores de las metaloproteasas de matriz.
AR041883A1 (es) Compuestos de piridopirimidinona, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
GEP20125548B (en) New dihidroindolone compounds, a process for its preparation and pharmaceutical compositions containing them
EA200800235A1 (ru) Новые трициклические соединения, способ их получения и фармацевтические композиции, которые их содержат
BR0109328A (pt) Inibidores de metaloprotease n-substituìdos, contendo cadeia lateral heterocìclica
BR0313734A (pt) Derivados do tiofeno, o seu processo de preparação e as composições farmacêuticas que os contêm
EA200701476A1 (ru) Новые гетероциклические соединения оксима, способ их получения и фармацевтические композиции, которые их содержат
AR002945A1 (es) Acidos 4-biarilbutirico o 5-biarilpentanoico sustituidos y sus derivados como inhibidores de las metaloproteasas de matriz, composicion que los contiene, y metodos para la preparacion de dichos compuestos
AR029001A1 (es) Derivados de bencil-3,4-metilendioxicinamico y el uso de los mismos para la manufactura de un medicamento
AR035599A1 (es) Compuestos 1,8-naftiridina, dihidroquinolina y piridol[1,2,3-de][1,4]benzoxazina sustituidos, medicamentos, agentes terapeuticos, metodos de produccion y usos en la produccion de un medicamento, de un agente antibacteriano y de un agente para tratar una enfermedad infecciosa
NO330964B1 (no) Kolkisosidanaloger
NO20083753L (no) Nye pyridinylaminoalkylen- og pyridinyloksyalkylen-syklopropanaminer, fremgangsmate for fremstilling derav og farmasoytiske sammensetninger inneholdende dem
FR2525597B1 (fr) Polymethylene diamines n,n'-substituees, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
AR052802A1 (es) Compuestos de benzotiazina y benzotiadiazina un procedimiento para su preparacion y composiciones farmaceuticas que los contienen
ES2234825T3 (es) Nuevos derivados heterociclicos o bencenicos del acido lipoico, su preparacion y su aplicacion como medicamentos.
ES2135351B1 (es) Derivados de 5-aroilnaftaleno.
AR001082A1 (es) Bencenosulfonilureas y bencenosulfoniltioureas sustituidas procedimiento para su preparación y su empleo para la producción de preparados farmacéuticos asi como preparados farmacéuticos que las contienen

Legal Events

Date Code Title Description
FG Grant, registration